TITLE: Antifungal Prophylaxis for Allogeneic Hematopoietic Stem Cell Transplant Recipients: Clinical Effectiveness and Guidelines

DATE: 22 December 2016

RESEARCH QUESTIONS

1. What is the clinical effectiveness of primary antifungal prophylaxis for standard risk patients with myeloablative allogeneic hematopoietic cell transplant recipients?

2. What are the evidence-based guidelines for antifungal prophylaxis for standard risk patients with myeloablative allogeneic hematopoietic cell transplant recipients?

KEY FINDINGS

One non-randomized study was identified regarding clinical effectiveness of primary antifungal prophylaxis for standard risk patients with myeloablative allogeneic hematopoietic cell transplant recipients.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2016, Issue 12), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2011 and December 6, 2016. Internet links were provided, where available.

The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that the Canadian Agency for Drugs and Technologies in Health (CADTH) could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
SELECTION CRITERIA

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

<table>
<thead>
<tr>
<th>Table 1: Selection Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Study Designs</strong></td>
</tr>
</tbody>
</table>

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

One non-randomized study was identified regarding clinical effectiveness of primary antifungal prophylaxis for standard risk patients with myeloablative allogeneic hematopoietic cell transplant recipients. No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, or evidence-based guidelines were identified.

Additional references of potential interest are provided in the appendix.

OVERALL SUMMARY OF FINDINGS

One non-randomized study compared patients who received preventative fluconazole and those who received no prophylaxis following allogenic stem cell transplantation. Invasive fungal infections were reported with similar frequency in both patient groups. The incidence of fungal infection, three year overall and disease-free survival, non-relapse mortality and graft versus host disease were similar in both groups. The authors suggested that prophylactic fluconazole may not be required in these patients.
REFERENCES SUMMARIZED

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses
No literature identified.

Randomized Controlled Trials
No literature identified.

Non-Randomized Studies


Guidelines and Recommendations
No literature identified.

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Non-Randomized Studies

Myeloablation Not Specified in Abstract


Alternate Intervention / No Prophylaxis


Evidence-Based Guidelines – Myeloablation Not Specified


Clinical Practice Guidelines – Methodology Not Specified


Review Articles
